仁和药业：10月13日召开董事会会议

Group 1 - The core point of the article is that Renhe Pharmaceutical (SZ 000650) held its third board meeting of the tenth session on October 13, 2025, to review the proposal for amending the "Independent Director Work System" [1] - For the first half of 2025, Renhe Pharmaceutical's revenue composition was 99.25% from the pharmaceutical industry and 0.75% from other businesses [1] - As of the report date, Renhe Pharmaceutical's market capitalization was 8.6 billion yuan [1]